Daniel Burgess, FRQA

Daniel Burgess has over two decades of experience in quality assurance and compliance roles within the pharmaceutical and healthcare industries.

Their most recent position is as Vice President of Quality Assurance at Verona Pharma, which they started in December 2022.

Prior to this, they worked at Policy & Medicine Compliance Update, where they served as an Editorial Board Member starting in January 2018.

From June 2021 to December 2022, Daniel worked as the Senior Director of Global Clinical Quality Assurance, Systems, and Compliance at NOVAVAX INC.

In 2020, they founded QAIRC, a company focused on enhancing quality assurance and communication for small to mid-sized GxP companies.

Before founding QAIRC, Daniel served as the Chief Compliance Officer at Pharm-Olam, LLC from October 2016 to October 2020. In this role, they provided global quality leadership and managed various aspects of quality systems, audits, inspection readiness, and training.

From 2013 to 2016, Daniel worked as the Senior Director of Corporate Compliance at Hospira, a Pfizer company. Daniel was responsible for directing corporate manufacturing audits across 18 facilities and played a key role in the company's acquisition by Pfizer.

Prior to their role at Hospira, Daniel worked as the Director of Quality Assurance and Regulatory Affairs at Thermo Fisher Scientific from 2011 to 2013, where they led efforts in training, validation, and quality assurance for critical biological materials.

From 2009 to 2010, Daniel held the position of Global Head of Clinical Quality Assurance at Alexion Pharmaceuticals, where they developed and implemented a global quality management system and auditing program.

From 1998 to 2008, Daniel worked at Pfizer in various roles, including Director of Quality Standards and Medical Education. In this position, they developed clinical audit capabilities, established quality management systems, and led global training programs.

Before joining Pfizer, Daniel worked as an International Auditor at Novartis, where they conducted audits of pharmaceutical activities and contributed to the development of quality systems.

Throughout their career, Daniel has received numerous awards and recognition for their contributions to quality assurance and compliance, including CRO Leadership Awards for Quality and Pfizer awards in mentorship, communication, and innovation.

Overall, Daniel Burgess has a comprehensive background in quality assurance and compliance, ranging from founding their own company to holding leadership positions in multinational pharmaceutical companies.

Daniel Burgess, FRQA has a diverse educational background. Daniel attended the University of Cambridge from 1994 to 1995, where they pursued a degree in Research Quality Assurance with a focus on GxP (Good Practice) standards. Prior to that, from 1985 to 1989, Daniel studied at the University of South Wales, specializing in Life Science and Pollution Monitoring. While no specific degree name is provided, their field of study was Biology/Biological Sciences, General. Before their university studies, Daniel Burgess attended Bay House in Gosport from 1979 to 1985, with no specified degree or field of study.

In addition to their formal education, Daniel has acquired numerous certifications. These include the Basic Safety Sciences certification in Pharmacoepidemiology, Clinical Pharmacology, Pharmacogenomics, and Toxicology Studies from DIA, obtained in February 2022. Daniel also obtained certifications in Basics of Signal Detection and Pharmacoepidemiology in January 2022, as well as certifications in Post-Marketing Safety Management and Pre-Marketing Clinical Trial Safety in the same month. Daniel Burgess achieved certifications in Safety Audits and Inspections in January 2022 and Drug Safety Regulatory Requirements and Introduction to Drug Safety in August 2021, all from DIA. Furthermore, they obtained several certifications in auditing and IT governance from The Institute of Internal Auditors Inc. during 2021 and 2022. Daniel also acquired certifications in Risk-Based Quality Management Essentials, Conflicts of Interest, and GCP for Clinical Trials with Investigational Drugs and Biologics (ICH Focus) from various institutions, further enhancing their expertise in the field.